Alignment Healthcare, Inc. insider trading
Every open-market purchase and sale by Alignment Healthcare, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Alignment Healthcare, Inc.’s insiders pay?
From April 1, 2021 to October 7, 2026, 35 insiders reported 3 open-market purchases and 133 sales not made under a pre-set plan in Alignment Healthcare, Inc. Twelve months after each purchase was reported, the shares were −57.6% against the S&P 500 on average (median −57.6%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −31.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 13, 2023 into $5,706 by November 2, 2026, −14.3% a year. It held shares 30% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,362 (+8.3% a year), and held throughout $20,581 (+22.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Maroney Dawn Christine | President | 0 | — | — | 22 | −24.6% (15) | September 11, 2026 |
| Kao John E | Chief Executive Officer | 1 | — | — | 11 | −32.1% (8) | March 19, 2026 |
| Freeman Robert Thomas | Chief Financial Officer | 0 | — | — | 11 | −33.2% (8) | March 28, 2025 |
| Scavo Robert L. | Chief Information Officer | 0 | — | — | 10 | −16.1% (5) | March 19, 2026 |
| General Atlantic (aln Hlth), L.P. | Director | 0 | — | — | 7 | −52.5% (7) | September 19, 2025 |
| Kardes Hakan | Chief Experience Officer | 0 | — | — | 7 | +2.3% (4) | March 28, 2025 |
| Kim Hyong | Chief Medical Officer | 0 | — | — | 7 | +7.3% (3) | October 7, 2026 |
| Konowiecki Joseph S | EVP, Corporate Affairs | 1 | −57.6% (1) | 0% | 6 | +3.3% (4) | September 18, 2026 |
| Joyce Christopher J | Chief Legal and Admin. Officer | 0 | — | — | 6 | +0.2% (3) | March 19, 2026 |
| Kumar Dinesh M. | Chief Med & Operating Officer | 0 | — | — | 6 | −51.0% (6) | March 31, 2023 |
| Burzacchi Sebastian | COO - Mgmt Services Org | 0 | — | — | 4 | +21.2% (2) | March 19, 2026 |
| Cross Richard A. | SVP, General Counsel | 0 | — | — | 3 | −46.9% (3) | March 31, 2023 |
| General Atlantic Partners 95, L.P. | Director | 0 | — | — | 3 | −51.0% (3) | September 19, 2025 |
| Wagner Andreas P. | Chief Human Resources Officer | 0 | — | — | 3 | +9.7% (2) | February 10, 2026 |
| Warburg Pincus Partners Gp LLC | Director | 0 | — | — | 3 | −49.1% (3) | August 24, 2022 |
| Furman Donald Steven | Chief Clinical Officer | 0 | — | — | 2 | −22.8% (2) | April 1, 2022 |
| General Atlantic Genpar, L.P. and related entities | 10% owner | 0 | — | — | 2 | −62.8% (1) | December 12, 2025 |
| Mcclellan Mark B. | Director | 0 | — | — | 2 | −39.6% (2) | November 24, 2021 |
| Warburg Pincus & Co. | Director | 0 | — | — | 2 | −62.9% (2) | September 20, 2022 |
| Warburg Pincus Xii Partners, L.P. | Director | 0 | — | — | 2 | −65.5% (2) | September 20, 2022 |
| Foster Michael Curtis | Chief Legal Officer | 0 | — | — | 1 | −63.0% (1) | April 8, 2021 |
| Gap Coinvestments Cda, L.P. | Director | 0 | — | — | 1 | −67.1% (1) | September 16, 2025 |
| Gap Coinvestments V, LLC | Director | 0 | — | — | 1 | −16.3% (1) | November 24, 2021 |
| Gapco Gmbh & Co Kg | Director | 0 | — | — | 1 | −63.1% (1) | April 1, 2021 |
| General Atlantic (spv) Gp, LLC | Director | 0 | — | — | 1 | −68.1% (1) | August 9, 2022 |
| General Atlantic, L.P. | Director | 0 | — | — | 1 | −63.0% (1) | April 8, 2021 |
| Head James M | Chief Financial Officer | 0 | — | — | 1 | — | April 8, 2026 |
| Kent Mark D. | President - MSO | 1 | — | — | 0 | — | June 2, 2026 |
| Margolis Jeffrey H | Director | 0 | — | — | 1 | −63.0% (1) | April 8, 2021 |
| Shrestha Rajesh | Pres., New Markets & CBO | 0 | — | — | 1 | −29.4% (1) | April 1, 2022 |
| Warburg Pincus LLC | Director | 0 | — | — | 1 | −63.1% (1) | April 1, 2021 |
| Warburg Pincus Private Equity Xii-B, L.P. | Director | 0 | — | — | 1 | −63.0% (1) | April 8, 2021 |
| Warburg Pincus Private Equity Xii-D, L.P. | Director | 0 | — | — | 1 | −16.3% (1) | November 24, 2021 |
| Wp Global LLC | Director | 0 | — | — | 1 | −62.6% (1) | August 16, 2022 |
| Wp Xii Partners, L.P. | Director | 0 | — | — | 1 | −63.1% (1) | April 1, 2021 |
When several insiders traded Alignment Healthcare, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Alignment Healthcare, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 8 selling crowds, −10.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| September 30, 2025 | 6 selling | +6.8% | +3.4% | −71.6% |
| March 31, 2025 | 9 selling | −34.4% | −26.1% | −22.6% |
| December 31, 2024 | 4 selling | +72.7% | +10.3% | +67.9% |
| March 31, 2023 | 5 selling | −17.8% | +5.4% | −58.4% |
| August 31, 2022 | 8 selling | −16.1% | −53.2% | −78.2% |
| April 29, 2022 | 7 selling | +53.1% | +40.1% | −30.9% |
| November 30, 2021 | 10 selling | −44.7% | −27.4% | −8.8% |
| April 30, 2021 | 13 selling | −26.9% | −35.6% | −63.8% |